{"id":774011,"date":"2026-07-02T09:49:09","date_gmt":"2026-07-02T09:49:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/774011\/"},"modified":"2026-07-02T09:49:09","modified_gmt":"2026-07-02T09:49:09","slug":"up-55-in-2026-why-this-asx-healthcare-stock-is-climbing-again","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/774011\/","title":{"rendered":"Up 55% in 2026! Why this ASX healthcare stock is climbing again"},"content":{"rendered":"

The Telix Pharmaceuticals Ltd (ASX: TLX<\/a>) share price is back on the move on Thursday.<\/p>\n

At the time of writing, the ASX healthcare stock is up 2.56% to $17.46.\u00a0<\/p>\n

That continues a strong run for shareholders, with Telix shares now up around 34% over the past month and 55% since the start of 2026.\u00a0<\/p>\n

The latest gain comes after the company released another update this morning, this time linked to one of its late-stage cancer programs.\u00a0<\/p>\n

Here are the details.<\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

FDA feedback clears next step<\/p>\n

According to the release<\/a>, Telix has reached an agreement with the FDA to move ahead with the next part of its ProstACT Global Phase 3 study in the US.<\/p>\n

The study is looking at TLX591-Tx, a targeted radiation treatment being developed for a serious form of prostate cancer.\u00a0<\/p>\n

This type of prostate cancer has spread to other parts of the body and keeps growing, even after treatment to reduce male hormone levels.<\/p>\n

Telix said the FDA reviewed safety data from the first part of the trial, including how much radiation was delivered to patients.\u00a0<\/p>\n

The regulator confirmed the data was enough for Telix to move into Part 2 of the study in the US.<\/p>\n

Part 2 is the randomised stage of the trial. It will test TLX591-Tx alongside existing prostate cancer treatments, including abiraterone, enzalutamide, or docetaxel.\u00a0<\/p>\n

What comes after the FDA review<\/p>\n

Keep in mind, this isn’t a product approval. Telix still needs to run the larger trial and prove the treatment works.<\/p>\n

Telix said the FDA agreed with the proposed clinical protocol and statistical framework across 3 standard-of-care treatment groups.\u00a0<\/p>\n

That gives the company a clearer plan for how the next part of the study will run and how the results will be measured.\u00a0<\/p>\n

It also helps Telix keep building the trial in the US, while recruitment continues in other approved regions.<\/p>\n

However, the company said Part 2 of the study still needs one more FDA review before it can begin.\u00a0<\/p>\n

What makes the treatment different?<\/p>\n

The treatment is aimed at PSMA, which is often found on prostate cancer cells.<\/p>\n

Telix describes TLX591-Tx as an antibody-based treatment, whereas other radiopharmaceutical therapies use a small molecule approach.<\/p>\n

The idea is to send radiation directly to the cancer cells being targeted.\u00a0<\/p>\n

Telix says the therapy is delivered over about 2 weeks and may be able to fit into existing treatment plans without too much disruption.<\/p>\n

Can the rally continue?<\/p>\n

After a 34% gain in a month, Telix shares may need a breather.<\/p>\n

The FDA update is positive, but the market is likely to focus on the data from the larger study from here.<\/p>\n

Until those results come through, the share price may move sideways as investors wait for the next major update.<\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"The Telix Pharmaceuticals Ltd (ASX: TLX) share price is back on the move on Thursday. At the time…\n","protected":false},"author":2,"featured_media":774012,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-774011","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/774011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=774011"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/774011\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/774012"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=774011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=774011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=774011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}